The total return over the past 12 months is +187.00% vs. +16.94% for the S&P 500. So far it's up +170.58% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +187.00% | +127.38% | +1.43% | N/A | N/A | N/A |
| Total Return CAGR | +187.00% | +127.38% | +1.43% | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Definium Therapeutics, Inc. (DFTX)
| Year | Start price | End price | DFTX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $13.39 | $36.23 | +170.58% | +14.51% | +156.07% |
| 2025 | $6.96 | $13.39 | +92.39% | +17.72% | +74.67% |
| 2024 | $3.66 | $6.96 | +90.16% | +24.89% | +65.27% |
| 2023 | $2.20 | $3.66 | +66.36% | +26.19% | +40.17% |
| 2022 | $20.70 | $2.20 | (89.37%) | (18.17%) | (71.20%) |
| 2021 | $45.75 | $20.70 | (54.75%) | +28.74% | (83.49%) |
| 2020 | $0.84 | $45.75 | +5346.43% | +18.37% | +5328.06% |
| 2019 | $0.66 | $0.84 | +27.27% | +31.22% | (3.95%) |
| 2018 | $4.46 | $0.66 | (85.20%) | (4.56%) | (80.64%) |
| 2017 | $8.24 | $4.46 | (45.87%) | +21.70% | (67.57%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
